Articles - FCS Hematology Oncology Review

Everybody’s Talking About Value-Based Health Care. Here’s What They’re Not Saying.

April 1, 2022

Thought-provoking oped highlighting the underbelly of buzzwords in healthcare today. The shift from volume to value that we’ve seen unfold over the past 3-5 years has moved front and center in many conversations, yet remains elusive insofar as its definition and implementation. This article rightly calls out that value is ultimately in the eye of the beholder, and yet there’s no disputing that doing what’s right for the patient trumps all.

Hospital-Administered Cancer Therapy Prices for Patients With Private Health Insurance

April 1, 2022

Analysis of 61 NCI-designated cancers demonstrate parenteral cancer drug price markups across all centers ranging between 188.4% to 633.6%. Only 27 centers publicly disclose payer-specific prices for cancer therapies as required by federal regulation. Authors recommend public policies to discourage excessive hospital price markups on patenteral chemotherapeutics to reduce financial burden on cancer treatment for patients.

Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial

March 1, 2022

Another PARP-inhibitor in this setting with reasonable toxicity profile and flexibility of efficacy for patients with mutated or non-mutated BRCA status. More options of therapy may decrease cost of treatment in a competitive market.

Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update

March 1, 2022

Important guideline update in a very common clinical scenario. Most practitioners prescribe antiresorptive therapy to prevent osteoporosis/osteopenia in the setting of aromatase-therapy inhibitors. Guidelines recommend consideration of bisphosphonate therapy irrespective of endocrine-tumor status.

Poziotinib for Patients With HER2 Exon 20 Mutant Non–Small-Cell Lung Cancer: Results From a Phase II Trial

March 1, 2022

Another trial corroborating the activity of poziotinib in this setting.

Poziotinib in Non–Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial

March 1, 2022

Importance of NGS testing cannot be overemphasized. Besides poziotinib (which has very reasonable clinical benefit), anti-HER2 combination therapy may be of value in this patient population. Studies are ongoing. Poziotinib-related rash and diarrhea are manageable with proper understanding and interventions.

Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial

March 1, 2022

DD-LPS is certainly a disease-process with unmet therapeutic needs. Selinexor versus BSC showed significant PFS improvement. Very interested in validation studies of CALB1 expression and potential combinations with Selinexor.

Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer

March 1, 2022

Another landmark study supporting the use CDK4/6 drugs along with endocrine therapy in the breast cancer metastatic setting. Missed opportunities insofar as adding CDK 4/6 drugs to endocrine blockade are a concern, since the OS survival difference is significant.

Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer

March 1, 2022

Very robust improvement of response rate, progression-free survival and decreased risk of death with trastuzumab deruxtecan versus trastuzumab emtansine. Early detection, knowledge about management and pre-treatment risk assessment of pulmonary toxicities are of paramount importance.

Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer

March 1, 2022

Practice-changing study for this specific patient population (see inclusion criteria) with approximately 30% risk reduction of death with excellent tolerability of treatment arm of this study.

Article Search

Everybody’s Talking About Value-Based Health Care. Here’s What They’re Not Saying.

Hospital-Administered Cancer Therapy Prices for Patients With Private Health Insurance

Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial

Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update

Poziotinib for Patients With HER2 Exon 20 Mutant Non–Small-Cell Lung Cancer: Results From a Phase II Trial

Poziotinib in Non–Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial

Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial

Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer

Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer

Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer

Keyword Search

Article Search

Cancer Types

Month Contributed

Show FCS Articles Only

Sort Order

Number of Posts

Menu

About This Site